Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allyl-{4-[3-(4-Bromo‑Phenyl)‑Benzofuran‑6‑Yloxy]‑but‑2‑Enyl}‑Methyl-Amine is a synthetic small molecule belonging to the phenylbenzofurans class of organic compounds. It has been catalogued in chemical and pharmaceutical databases (e.g., DrugBank, ChEMBL, PubChem), but there is no evidence of clinical use or approval for any medical indication. The compound is considered experimental and has not advanced beyond preclinical or early research stages. Its mechanism of action, biological targets, pharmacological activity, and therapeutic potential have not been established in the literature or public drug development pipelines[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine.